Follicular Lymphoma highlights of the ASH 2023 Congress

Professor Carla Casulo summarizes the most important highlights in the field of Follicular Lymphoma treatment after the 65th American Society of Hematology Annual Meeting.

Highlights of the ASH 2023 Congress

Professor Mikkael Sekeres summarizes the most important highlights that presented at the 65th American Society of Hematology Annual Meeting.

Present and future of Multiple Myeloma management

Professor Xavier Leleu explains the present and future of Multiple Myeloma management, how new regiments, new treatments will change how we treat patients.

Ibrutinib-Venetoclax Combination Found Effective Against Mantle Cell Lymphoma

Professor Michael Wang explains their findings that combining ibrutinib and venetoclax improves progression-free survival and remission rates in patients with mantle cell lymphoma.

Real-World Outcomes With Brexucabtagene Autoleucel

Professor Swetha Kambhampati on Mantle Cell Lymphoma: Real-World Outcomes With Brexucabtagene Autoleucel.

Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia - report from ASH2023

Professor on frontline treatment with targeted agents in patients with Chronic Lymphocytic Leukemia.

Dramatically Worse Myeloma Outcomes in Real World vs. Trials

Dr. Alissa Visram on the presented the data during 65th American Society of Hematology Annual Meeting. Patients with multiple myeloma who were treated in the real world had 44% worse progression-free survival and 75% worse overall survival than patients treated on clinical trials, according to a pooled analysis of efficacy versus effectiveness for seven MM regimens.

Multiple Myeloma highlights of ASH 2023 Congress

Professor Andrzej Jakubowiak summarizes the most important highlights in the field of MultiplMyeloma treatment at the 65th American Society of Hematology Annual Meeting.

Chronic Myeloid Leukemia highlights of ASH 2023 Congress

Professor Giuseppe Saglio summarizes the most important highlights in the field of Chronic Myeloid Leukemia treatment at the 65th American Society of Hematology Annual Meeting.

Acute myeloid leukemia highlights of ASH 2023 Congress

Professor Eunice S. Wang summarizes the most important highlights in the field of Acute Myeloid Leukemia treatment at the 65th American Society of Hematology Annual Meeting.

Chronic Myeloid Leukemia: Novel Therapeutic Approaches

Professor Carmen Fava summarizes the therapeutic novelties of Chronic Myeloid Leukemia management at the 65th American Society of Hematology Annual Meeting.

Non-Hodgkin Lymphoma highlights of the ASH 2023 Congress

Professor Umberto Vitolo summarizes the most important highlights in the field of Non-Hodgkin Lymphoma treatment at the 65th American Society of Hematology Annual Meeting.

Diagnostic and Therapeutic Novelties of Multiple Myeloma Management

Professor Enrique Ocio summarizes the diagnostic and therapeutic novelties of Multiple Myeloma management at the 65th American Society of Hematology Annual Meeting.

Acute myeloid leukemia highlights of the ASH 2023 Congress

Professor Agnieszka Wierzbowska summarizes the most important highlights in the field of acute myeloid leukemia treatment at the 65th American Society of Hematology Annual Meeting.

State of the art ALL treatement in 2023

Professor Marlise R. Luskin summarizes the state of the art acute lymphoblastic leukemia  treatement at the 65th American Society of Hematology Annual Meeting.

Revumenib Found Effective Against High-Risk KMT2Ar Acute Leukemia

Professor Ibrahim Aldoss explains that patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2a gene, a genetic marker known as KMT2Ar, who were treated with revumenib saw an overall response rate of 63%, according to results from a phase II trial being reported during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant (MAIA)

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Best of ASH

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Multicenter Microbiota Analysis Indicates That Pre-HCT Microbiota Injury Is Prevalent across Geography and Predicts Poor Overall Survival

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)